4 Incidental Breast Cancer on Chest CT: Is the Radiology Report Enough?

Publication
Article
Miami Breast Cancer Conference® Abstracts Supplement38th Annual Miami Breast Cancer Conference® - Abstracts
Volume 35
Issue suppl 1
Pages: 39-40

Joley Beeler, MD1; Onalisa Winblad, MD1; Carissa Walter, MPH1; Lauren Clark, MS2; Marc Inciardi, MD1; Ashley Huppe, MD1; Jason Gatewood, MD1; Allison Aripoli, MD1

1Department of Radiology, University of Kansas Medical and Cancer Centers, Kansas City, KS.

2Department of Biostatistics & Data Science, University of Kansas Medical, Kansas City, KS.

Background

The purpose of this study was to determine the frequency of incidental breast lesions reported on chest CT for which breast imaging follow-up was recommended, the follow-up adherence rate, and the subsequent breast malignancy rate. In addition, the relationship between the strength of follow-up recommendation verbiage and follow-up rate was also explored.

Material and Methods

A retrospective review was conducted of 30,224 chest CT reports at a single academic institution from July 1, 2018, through June 30, 2019, to identify reports containing the word(s) “breast” and/or “mammogram.” Patients with recently diagnosed or known prior history of breast malignancy were excluded. The reports were reviewed to identify those with a recommendation for breast imaging follow-up, patient adherence to the recommendation, the subsequent Breast Imaging Reporting and Data System (BI-RADS) assessment, and diagnosis if tissue sampling was performed. Adherence was defined as follow-up diagnostic breast imaging performed within 6 months of initial CT recommendation.

Results

A follow-up recommendation for breast imaging was included in chest CT reports of 210 patients without prior history or recent diagnosis of breast cancer. Forty-eight patients (23%) received follow-up dedicated breast imaging within 6 months. For these 48 patients, recommendation verbiage in the CT report was absolute in 69% and optional in 31%. The breakdown of BI-RADS assessments following subsequent diagnostic breast imaging was: 5 BI-RADS 1 (10%), 29 BI-RADS 2 (60%), 5 BI-RADS 3 (10%), 6 BI-RADS 4 (13%), and 3 BI-RADS 5 (6%) assessments. All of the patients assessed as BI-RADS 4 or 5 underwent image-guided biopsy with 7 cases of malignancy diagnosed. There was no significant difference in follow-up adherence when comparing report verbiage characteristics (P = .4624; 2 test).

Conclusions

Only 23% of patients with an incidental breast finding on chest CT actually returned for recommended breast imaging indicating a significant opportunity to improve patient outcomes. Incidental breast cancer was diagnosed in 15% (7/48) of patients who underwent follow-up breast imaging as a result of a chest CT report recommendation. In this sample, the strength of recommendation characterized by CT report verbiage (absolute vs optional) did not improve follow-up adherence. Future efforts to track incidental breast findings detected on chest CT with possible referring provider and patient outreach to ensure follow-up may have greater impact on the diagnosis of previously unsuspected breast cancer.

Expert Commentary

Expert Commentary

Articles in this issue

1 The Tolerance of CREATE-X Capecitabine Dosing in a United States TNBC Patient Population
1 The Tolerance of CREATE-X Capecitabine Dosing in a United States TNBC Patient Population
6 Survival Benefit of Eribulin, But Not Capecitabine, for Metastatic Breast Cancer Is Associated With Baseline Absolute Lymphocyte Count in Peripheral Blood
6 Survival Benefit of Eribulin, But Not Capecitabine, for Metastatic Breast Cancer Is Associated With Baseline Absolute Lymphocyte Count in Peripheral Blood
7 Evaluation of the 21-Gene Recurrence Score (RS) Assay Results Following Successful Intraoperative Radiation Therapy (IORT) Treatment of Patients With Early-Stage Breast Cancer
7 Evaluation of the 21-Gene Recurrence Score (RS) Assay Results Following Successful Intraoperative Radiation Therapy (IORT) Treatment of Patients With Early-Stage Breast Cancer
8 Concordance of Tumor Response with Eribulin Use in Real-World Clinical Practice
8 Concordance of Tumor Response with Eribulin Use in Real-World Clinical Practice
13 Real-world Treatment Patterns and Tumor Response of Palbociclib Plus an Aromatase Inhibitor for Metastatic Breast Cancer: Flatiron Database Analysis
13 Real-world Treatment Patterns and Tumor Response of Palbociclib Plus an Aromatase Inhibitor for Metastatic Breast Cancer: Flatiron Database Analysis
14 Real-World (RW) Treatment Patterns and Clinical Effectiveness of Palbociclib (PAL) Plus an Aromatase Inhibitor (AI) as First-Line Therapy in Advanced/ Metastatic Breast Cancer (A/MBC): Analysis From Syapse Learning Health Network
14 Real-World (RW) Treatment Patterns and Clinical Effectiveness of Palbociclib (PAL) Plus an Aromatase Inhibitor (AI) as First-Line Therapy in Advanced/ Metastatic Breast Cancer (A/MBC): Analysis From Syapse Learning Health Network
25 A Retrospective Cohort Study of Demographic, Clinical, and Treatment Characteristics of Patients With Metastatic Breast Cancer Who Have Received PARP Inhibitors
25 A Retrospective Cohort Study of Demographic, Clinical, and Treatment Characteristics of Patients With Metastatic Breast Cancer Who Have Received PARP Inhibitors
28 Primary Outcome Analysis of Invasive Disease-Free Survival for monarchE: Abemaciclib Plus Adjuvant Endocrine Therapy for High-Risk Early Breast Cancer
28 Primary Outcome Analysis of Invasive Disease-Free Survival for monarchE: Abemaciclib Plus Adjuvant Endocrine Therapy for High-Risk Early Breast Cancer
30 Open-Label, Phase 1 Study to Evaluate Duration of Severe Neutropenia After Same-Day Dosing of Eflapegrastim in Patients With Early- Stage Breast Cancer (ESBC) Receiving Docetaxel and Cyclophosphamide
30 Open-Label, Phase 1 Study to Evaluate Duration of Severe Neutropenia After Same-Day Dosing of Eflapegrastim in Patients With Early- Stage Breast Cancer (ESBC) Receiving Docetaxel and Cyclophosphamide
35 Decreased Epithelial Mesenchymal Transition Process After AGTR-1 Gene Edition By Crispr/Cas9, Losartan, and PARP Inhibitor Treatment In Breast Cancer Cell Line
35 Decreased Epithelial Mesenchymal Transition Process After AGTR-1 Gene Edition By Crispr/Cas9, Losartan, and PARP Inhibitor Treatment In Breast Cancer Cell Line
37 Treatment Outcomes Using Neoadjuvant Chemotherapy for HER2-Positive Breast Cancer in African American and Hispanic Women
37 Treatment Outcomes Using Neoadjuvant Chemotherapy for HER2-Positive Breast Cancer in African American and Hispanic Women
42 The United States Retrospective Claims Database Analysis of Demographic, Clinical, and Treatment Characteristics of Metastatic Breast Cancer Patients receiving Olaparib
42 The United States Retrospective Claims Database Analysis of Demographic, Clinical, and Treatment Characteristics of Metastatic Breast Cancer Patients receiving Olaparib
43 Lobular Cancer Responsiveness to Chemotherapy Is Equivalent to That of Ductal Cancer With Similar Genomic Profiles: An NCDB Analysis
43 Lobular Cancer Responsiveness to Chemotherapy Is Equivalent to That of Ductal Cancer With Similar Genomic Profiles: An NCDB Analysis
44 Drivers of Oncologist Treatment Selection in HR+/HER2- Metastatic Breast Cancer
44 Drivers of Oncologist Treatment Selection in HR+/HER2- Metastatic Breast Cancer
45 Neoadjuvant Chemotherapy Use in Elderly Patients
45 Neoadjuvant Chemotherapy Use in Elderly Patients
Related Content